CN104762325B - A kind of method of IFNAR2 genes in 1 cell lines of silence DF - Google Patents
A kind of method of IFNAR2 genes in 1 cell lines of silence DF Download PDFInfo
- Publication number
- CN104762325B CN104762325B CN201510143519.XA CN201510143519A CN104762325B CN 104762325 B CN104762325 B CN 104762325B CN 201510143519 A CN201510143519 A CN 201510143519A CN 104762325 B CN104762325 B CN 104762325B
- Authority
- CN
- China
- Prior art keywords
- ifnar2
- rnai
- genes
- cell lines
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 23
- 241000700605 Viruses Species 0.000 claims abstract description 38
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 25
- 101150074051 ifnar2 gene Proteins 0.000 claims abstract description 10
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 8
- 230000014509 gene expression Effects 0.000 claims abstract description 8
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 6
- 230000003612 virological effect Effects 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 14
- 230000029087 digestion Effects 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 7
- 238000010790 dilution Methods 0.000 claims description 6
- 239000012895 dilution Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 5
- 239000012097 Lipofectamine 2000 Substances 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 108091030071 RNAI Proteins 0.000 claims description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000001638 lipofection Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 229960005486 vaccine Drugs 0.000 abstract description 9
- 206010064097 avian influenza Diseases 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000000427 antigen Substances 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 6
- 108091007433 antigens Proteins 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 238000004113 cell culture Methods 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 47
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 16
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 5
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 108010054267 Interferon Receptors Proteins 0.000 description 2
- 102000001617 Interferon Receptors Human genes 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 238000012272 crop production Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- -1 only 1 subunit Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036413 temperature sense Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of method of IFNAR2 genes in 1 cell lines of silence DF., first according to IFNAR2 genes, multiple siRNA of designated rna interfered target sequence, further filter out the siRNA that low IFNAR2 gene expressions are struck in mRNA level in-site for it；The slow virus carrier containing IFNAR2 RNAi genes is built again；By above-mentioned slow virus carrier, IFNAR2RNAi gene mediateds are entered into 1 cell lines of DF, the expression of silence IFNAR2 genes, improves viral titer of the avian influenza virus in 1 cell lines of DF.The method can improve amount of antigen of the avian influenza virus in 1 cell lines of DF up to 5 10 times, substantially reduce production of vaccine cost, it can not only solve the problems, such as that vaccine antigen amount deficiency and production cost are higher, and promote the research and development process of bird flu bioreactor cell culture technology.
Description
Technical field
The present invention relates to interferon receptors 2 in a kind of silence DF-1 cell lines (Interferon receptor 2,
IFNAR2) the method for gene, for improving viral titer of the avian influenza virus in the cell line, belongs to biological technical field.
Background technology
As the important epidemic disease of the poultry such as the fast development of intensive culture industry, bird flu just becomes public health security field
Focus, from source control epidemic disease be current prevention and control strategy the most important thing.It was verified that vaccine immunity and quick detection are
The most effective measure of the great animal epidemic of prevention and control.It is domestic at present still main since the titre of avian influenza virus cell culture is relatively low
Vaccine is produced using fowl embryo, efficiency is low, energy consumption is high, and there are the possibility of the pollution of exogenous virus.China's agricultural " 12th Five-Year Plan " planning
Great Field of Animal Epidemic Disease Control technical research and crop production safety are included in great crucial skill with Quality Control Technology research
Art is tackled key problems.
DF-1 cells be a kind of stabilization, without oncogene, the chicken embryo fibroblasts system that can pass on, cellular morphology is in
Threadiness, the cell lack avian leukosis virus, and sarcoma virus endogenous gene, is widely used in animal virus research, vaccine
The numerous areas such as development and cancer research.Interferon (Interferon, IFN) is that body cell is subject to virus or other inducers
The secreting type glycoprotein with biological activities such as antiviral, immunological regulation, suppressing cell reproductions for acting on and producing, is broadly divided into
IFN-α、IFN-β、IFN-γ.Wherein IFN-α, the cell surface receptor of IFN-β are I type IFNAR, by IFNAR1 and IFNAR2 two
Bar chain forms, and wherein IFNAR1 is an important subunit protein of IFNAR, only 1 subunit, and IFNAR2 is sub- single by 3
Position composition, IFNAR1 and IFNAR2 when forming heterodimer coexpression could mediated signal transduction, individualism cannot play life
Thing function.Research shows that IFN specifically binds with cell surface receptor and mediates signal transduction through JAK-STAT approach, passes through
The approach such as PKR, Mx and ADAR-1 play antivirus action.Therefore, IFNAR2 genes in a kind of silence DF-1 cell lines are established
Method, can effectively improve viral titer of the avian influenza virus in DF-1 cell lines, so that production of vaccine cost is reduced, for me
The prevention and control of state's bird flu have important practical significance.
The content of the invention
The purpose of the present invention is overcome deficiency present in existing avian influenza vaccine production, there is provided a kind of silence DF-1 cells
The method of IFNAR2 genes in system, can improve amount of antigen of the avian influenza virus in DF-1 cell lines up to 5-10 times, not only can be with
Solve the problems, such as that vaccine antigen amount deficiency and production cost are higher, and promote bird flu bioreactor cell culture technology
Research and development process.
The technical scheme is that：A kind of method of IFNAR2 genes in silence DF-1 cell lines, it is characterized in that：
(1) according to IFNAR2 genes, multiple siRNA of designated rna interfered target sequence, further filter out mRNA level in-site
On strike the siRNA of low IFNAR2 gene expressions；
(2) structure expresses the slow virus carrier of the IFNAR2 gene siRNAs (IFNAR2RNAi genes) of above-mentioned screening；
(3) by above-mentioned slow virus carrier, IFNAR2 gene siRNAs (IFNAR2RNAi genes) are imported into DF-1 cells
System, the expression of silence IFNAR2 genes, improves viral titer of the avian influenza virus in DF-1 cell lines.
Further, the screening technique of the step (1) is：By multiple siRNA insertion pLKO.1-TRC clones of design
In carrier, DF1 cells are transfected, then harvests and extracts cell total rna, using fluorescence quantifying PCR method screening mRNA level in-site interference
Effective siRNA of IFNAR2 genes.
Further, the siRNA that step (1) screening obtains is sh3：5′-TACACAAGGCGTGATATCGTA-3′；
Further, the slow virus carrier of the step (2) is LV-IFNAR2-RNAi；
The construction method of above-mentioned slow virus carrier is to comprise the following steps：
1) synthesizing single-stranded DNA oligo are designed according to the DNA sequence dna of above-mentioned siRNA, annealed pairs produce double-strand, then pass through
Restriction enzyme site contained by both ends is directly connected into the RNAi slow virus carriers GV248 after digestion, and connection product is transferred to and is prepared
Bacterium competent cell, PCR method identification positive recombinant plasmid GV248-IFNAR2；
Above-mentioned double-strand is：
IFNAR2-RNAi-1：5′-CCGG TACACAAGGCGTGATATCGTA CTCGAG
TACGATATCACGCCTTGTGTA TTTTTG-3′
IFNAR2-RNAi-2：5′-AATTCAAAAA TACACAAGGCGTGATATCGTA CTCGAG
TACGATATCACGCCTTGTGTA-3′
2) recombinant plasmid GV248-IFNAR2 is largely extracted, after being mixed with helper plasmid pHelper1.0, pHelper2.0
293T cells are transfected by liposome (Lipofectamine2000), collect the cell supernatant of culture 48h, through centrifugation, supernatant
Slow virus carrier LV-IFNAR2-RNAi is obtained after liquid filtering.
Further, the step (3) by slow virus carrier LV-IFNAR2-RNAi by IFNAR2 gene siRNAs
(IFNAR2RNAi genes) is mediated into DF-1 cell lines, is comprised the following steps：
1) by DF-1 cell inoculations into Tissue Culture Dish, when density to be grown is up to 70%, it is inoculated with slow virus LV-
IFNAR2-RNAi；
2) with containing the 10%FBS DMEM culture mediums of 10 μ g/mL polybrenes dilution LV-IFNAR2-RNAi to final concentration of 5
×106PFU/mL, and then by 10 times of doubling dilutions, obtain the different virus titer of at least three, be seeded to DF-1 cells respectively
In；Concurrently set positive-virus control；
3) 5%CO under the conditions of the DF-1 cells for being inoculated with LV-IFNAR2-RNAi being put 37 DEG C2Culture 4h is maintained, is changed to and contains
5%FBS DMEM culture mediums, continue culture to 48h, replace the 10%FBS DMEM culture mediums containing 4 μ g/mL puromycins, screening
Go out positive cell clone.
The present invention has following advantages：
1. the present invention builds three shRNA into pLKO.1-TRC cloning vectors, by transfecting harvest and extracting cell
Total serum IgE, using effective siRNA of quantitative fluorescent PCR screening mRNA level in-site interference IFNAR2 genes, provides for screening siRNA
A kind of quick, accurate, high-throughout method.
2. the present invention utilizes slow virus carrier system, the shRNA for disturbing IFNAR2 genes is quickly connected to slow virus carries
System is united, and a kind of slow virus containing IFNAR2RNAi genes is obtained by transfecting.
3. the present invention is mediated IFNAR2RNAi to DF-1 cells by slow virus, establish in a kind of silence DF-1 cell lines
The method of IFNAR2 genes, can improve amount of antigen of the avian influenza virus in DF-1 cell lines up to 5-10 times, substantially reduce vaccine
Production cost, can not only solve the problems, such as that vaccine antigen amount deficiency and production cost are higher, and promote bird flu biology anti-
Answer the research and development process of device cell culture technology.
Brief description of the drawings
Fig. 1 is three siRNA of design screening in the position of IFNAR2 genes and the effective shRNA filtered out (sh3)；
Fig. 2 be pLKO.1 plasmids through Age I and EcoR I double digestion agarose gel electrophoresis products, wherein M swimming lanes are DNA
marker DL 15000；1st swimming lane is pLKO.1 plasmid Age I and EcoR I digestion products；
Fig. 3 is that pLKO.1-TRC-IFNAR2 plasmids identify product through EcoR I and Nco I double digestions, and wherein M swimming lanes are
DNA marker DL 15000；1st swimming lane is pLKO.1-TRC-IFNAR2 plasmids through EcoR I and Nco I double digestion products；
Fig. 4 is the △ Ct values of IFNAR2 effective shRNAs screening fluorescence quantitative PCR detection；
Fig. 5 is fluorescence microscopy Microscopic observation slow virus LV-IFNAR2-RNAi infection 293T cells；Wherein left figure is common
The light visual field, right figure are the fluorescence visual field；
Fig. 6 is 1215 plants of TCID in DF-1, DF-1 △ IFNAR2 cells of avian influenza virus50Measure.
Embodiment
First, the siRNA screenings of IFNAR2 genetic transcriptions are disturbed
1st, the design and synthesis of the oligonucleotide sequence of the siRNA of IFNAR2 genes are disturbed
According to the IFNAR2 gene orders and addgene slow virus carrier construction procedures logged in Genbank, in
http:SiRNA (such as Fig. 1 of 3 RNA interfered target sequences of //jura.wi.mit.edu/bioc/siRNAext/ website designs
It is shown), while control group Scramble is set up, sequence is as follows：sh1：5′-AATAACCTCTGTAGAGATCAT-3′(SEQ
No.1)；sh2：5′-AA AGACACGGATAGTGAGTTA-3′(SEQ No.2)；sh3：5′-TA
CACAAGGCGTGATATCGTA-3′(SEQ No.3)；Scramble：CCTAAGGTTAAGTCGCCCTCG (SEQ No.4), root
According to pLKO.1-TRC cloning vector characteristics, its corresponding complementary series of the DNA sequence dna of siRNA is connected with loop sequences to be formed
Positive-sense strand and antisense strand, and joint sequence is introduced at both ends, shRNA is formed by annealing.Sequence is by precious bioengineering (Dalian)
Co., Ltd synthesizes.
2nd, structure and the identification of IFNAR2 gene pLKO.1-TRC-IFNAR2 carriers are disturbed
With reference to Addgene companies pLKO.1-TRC cloning vector specifications, by pLKO.1-TRC cloning vectors in 37 DEG C of warps
Age I digestion 2h, recycling carrier segments, with EcoR I digestion 2h, obtain the fragment of 7kb, 1.9kb (such as Fig. 2 institutes respectively in 37 DEG C
Show).Recycling 7kb fragments are connected overnight with 16 DEG C of the shRNA sequences that annealing is formed, and convert DH5 α, picking monoclonal bacterium colony, passes through
Plasmid pLKO.1-TRC-IFNAR2 is extracted after night culture, is identified with EcoR I and Nco I double digestions, 1% agarose gel electrophoresis
Obtain the fragment (as shown in Figure 3) of 2kb, 5kb.The positive clone of identification utilizes pLKO.1 sequencing primers (5 '-CAA GGC TGT
TAG AGA GAT AAT TGG A-3 ' SEQ No.5) it is sequenced.
3rd, detection primer design and synthesis
Using SYBR Green I fluorescent quantitations PCR (ABI 7300) expand target gene IFNAR2, concurrently set internal reference β-
actin.Wherein IFNAR2 fragment lengths are 134bp, with reference to NM_204858.1 sequences；β-actin fragment lengths are 113bp, ginseng
NM_205518.1 sequences are examined, primer sequence is as follows：
IFNAR2 F：AACACTGAGAACAGTTGGTGAAGA(SEQ No.6)；
IFNAR2 R：TTAGAGATGCAGTGACCATAACAGA(SEQ No.7)；
β-actin F：ATTGTCCACCGCAAATGCTTC(SEQ No.8)
β-actin R：AAATAAAGCCATGCCAATCTCGTC(SEQ No.9).
The collimation that I quantitative fluorescent PCR the primers of SYBR Green are expanded using △ Ct verification target genes with internal reference, with
Upper primer sequence is synthesized by precious bioengineering (Dalian) Co., Ltd.
4th, plasmid pLKO.1-TRC-IFNAR2 is transfected
24h prepares DF-1 cell monolayers in 12 porocyte culture plates before transfection, is turned when cell growth is to 80%
Dye：The endotoxin-free plasmid pLKO.1-TRC-IFNAR21.2 μ g extracted with kit are dissolved in 100 μ L OPTI-MEM and subtract serum
In culture medium, separately take 3 μ L Lipofectamine2000 (liposome) to be dissolved in 100 μ L OPTI-MEM and subtract in blood serum medium, will
Plasmid mixed liquor is added in liposome mixed liquor and mixed, and 20min is made in room temperature sense, and the serum-free DMEM trainings of 2h replacements before transfection are abandoned in suction
Base is supported, plasmid and liposome mixed liquor is added, puts 37 DEG C of 5%CO2Under the conditions of continue to cultivate 5.5h, replace 3%FBS DMEM training
Support to 48h, collect cell extraction total serum IgE.
5th, the transcriptional level of fluorescence quantifying PCR method detection IFNAR2
Using a small amount of extraction agent box (AXYGEN) the extraction cell total rnas of RNA, the RNA of acquisition is through ReverTra Ace
QPCR RT Master Mix with gDNA Remover reverse transcriptions are c DNA, after 2 times of dilutions, using SYBR Green I
Quantitative fluorescent PCR (ABI 7300) expands target gene IFNAR2, concurrently sets internal reference β-actin.Amplification condition is 95 DEG C of pre- changes
Property 45s, 10s, 55 DEG C of renaturation 20s, 72 DEG C of extension 20s of 95 DEG C of denaturation, 40 circulations, do 3 repetitions per a sample.Made with △ Ct values
For the difference between shRNAs and the Scramble expression of Indexes Comparison difference target gene, as a result filter out IFNAR2-sh3 and exist
The expression (as shown in Figure 4) for having struck IFNAR2 genes low in mRNA level in-site.
2nd, the slow virus carrier structure containing IFNAR2RNAi genes
1st, built for IFNAR2RNAi Gene Lentiviral Vectors
It is as follows according to the DNA sequence dna of the siRNA filtered out design synthesis shRNA, synthesizing single-stranded DNA oligo, sequence：
IFNAR2-RNAi-1：5′-CCGG TACACAAGGCGTGATATCGTA CTCGAG
TACGATATCACGCCTTGTGTA TTTTTG-3 ' (SEQ No.10),
IFNAR2-RNAi-2：5′-AATTCAAAAA TACACAAGGCGTGATATCGTA CTCGAG
TACGATATCACGCCTTGTGTA-3′(SEQ No.11)；
By the single-stranded IFNAR2-RNAi-15 μ L (20 μM) of synthesis, IFNAR2-RNAi-25 μ L (20 μM), 10 × buffer
2(NEB)5μL、35μL ddH2O, 90 DEG C of water-bath 15min, cooled to room temperature anneal to form DNA fragmentation.Connected by T4DNA
Connect enzyme to be connected the carrier GV248 that Age I, EcoR I double digestions linearize with the DNA fragmentation annealed, obtain GV248-
IFNAR2.Through 16 DEG C of connections overnight, convert to competence bacteria DH5 α, positive colony is identified by PCR method, and to positive colony
Carry out determination and analysis of sequence.
2nd, LV-IFNAR2-RNAi slow virus packaging and titer determination
The recombinant virus plasmid of a large amount of coding lentiviral particles for preparing high-purity endotoxin-free, and two kinds of auxiliary packagings
Original paper vector plasmid.24h prepares individual layer 293T cells before transfection, and cell density is adjusted as 1.2 × 10 using DMEM containing 10%FBS7
Cell/6mL, is inoculated in 60mm Tissue Culture Dish, 37 DEG C of 5%CO2It can be used for turning when culture to cell density reaches 70%-80%
Dye, cell culture medium is changed to serum free medium by 2h before transfection.Plasmid GV248-IFNAR2, pHelper1.0 is taken to carry respectively
Body, pHelper2.0 carriers, which are respectively 10 μ g, 7.5 μ g, 5 μ g are mixed with OPTI-MEM makes cumulative volume be 1mL, and room temperature acts on
5min.Take 20 μ L liposomes (Lipofectamine2000) to subtract blood serum medium with 1mL OPTI-MEM to mix, room temperature effect
5min.Diluted plasmid and Lipofectamine2000 are gently overturned and mixed, room temperature effect 20min makes to form transfection compound
Thing.Transfection composite is transferred to 293T cells, 37 DEG C of 5%CO2Transfection composite is discarded after culture 8h, is washed with 5mL PBS
Once, 10%FBS DMEM culture mediums are changed to, continue to collect 293T cell supernatants, 4 DEG C of centrifugations of 4000g after cultivating 48h
10min, supernatant are filtered through 0.45 μm of filter, and -80 DEG C of preservations, LV-IFNAR2-RNAi is named as by the slow virus of acquisition.Take disease
10 μ l of toxogen liquid, add in 90 μ l plasma-free DMEM mediums, and 10 times of doubling dilutions, are seeded in 96 orifice plates successively, and culture is extremely
4d observation luciferase expression situations (as shown in Figure 5), calculating virus titer is 3E+8TU/mL.
3rd, the screening and verification of lentivirus mediated IFNAR2RNAi genes DF-1 cell lines
1st, the screening of lentivirus mediated IFNAR2RNAi genes DF-1 cell lines
Individual layer DF-1 cells are prepared, are seeded in 60mm Tissue Culture Dish, 37 DEG C of 5%CO2Culture to stand density reaches
When 70%, the DMEM culture mediums containing 10 μ g/mL Polybrene (polybrene) are replaced.With containing 10 μ g/mL Polybrene's
10%FBS DMEM culture mediums suitably dilute slow virus, make LV-IFNAR2-RNAi slow virus final concentrations be respectively 5 ×
106PFU/mL、5×105PFU/mL、5×104PFU/mL, is seeded in DF-1 Tissue Culture Dish respectively, inoculum concentration 1.0mL/
Hole, while negative control virus CON077 is inoculated with, final concentration of 5 × 105PFU/mL.LV-IFNAR2-RNAi slow virus will be inoculated with
DF-1 cells be placed in 37 DEG C under the conditions of 5%CO2Culture 4h is maintained, the DMEM culture mediums of 5%FBS is changed to, continues culture extremely
48h, replaces the 10%FBS DMEM containing 4 μ g/mL Purocydin, and positive cell is filtered out by fluorescence signal and medicine pressurization
Clone, is named as DF-1 △ IFNAR2.
2nd, by 1215 plants of (China Animal Health and Epidemiology Center preservation chicken/Jiangsu/ of avian influenza virus
P278/2014H5N2 DF-1, DF-1 △ IFNAR2 cells) are inoculated with 0.1MOI, take the virus of 24h, 48h, 72h after inoculation respectively
Liquid, freeze thawing are inoculated with DF-1 cells, measure its TCID afterwards three times50Value, and repeated three times, the results showed that H5N2 is in DF-1 △
TCID in IFNAR2 cells50Higher than DF-1 cells (being shown in Table 1 and Fig. 6), wherein DF-1 △ IFNAR2 cell inoculations 24h, 48h
Virus titer is 1.1 times of DF-1 cell culture.
1 TCID of table50Measurement result
Table 1 Results of TCID50test(0.1mL)
Claims (3)
1. a kind of method of IFNAR2 genes in silence DF-1 cell lines, it is characterized in that,
(1) according to IFNAR2 genes, multiple siRNA of designated rna interfered target sequence, further filter out in mRNA level in-site and strike
The DNA sequence dna of the siRNA of low IFNAR2 gene expressions, the siRNA screened are 5 '-TA CACAAGGCGTGATATCGTA-
3′；
(2) structure expresses the slow virus carrier LV-IFNAR2-RNAi of the IFNAR2 gene siRNAs of above-mentioned screening；
The construction method that the slow virus carrier is LV-IFNAR2-RNAi is：
1) synthesizing single-stranded DNA oligo are designed according to the DNA sequence dna of the siRNA of screening, annealed pairs produce double-strand, then pass through two
The contained restriction enzyme site in end is directly connected into the RNAi slow virus carriers GV248 after digestion, and connection product is transferred to what is prepared
Bacterium competent cell, PCR method identification positive recombinant plasmid GV248-IFNAR2；
The double-strand is：
IFNAR2-RNAi-1：5′-CCGG TACACAAGGCGTGATATCGTA CTCGAG TACGATATCACGCCTTGTGTA
TTTTTG-3′；
IFNAR2-RNAi-2：5′-AATTCAAAAA TACACAAGGCGTGATATCGTA CTCGAG
TACGATATCACGCCTTGTGTA-3′；
2) recombinant plasmid GV248-IFNAR2 is largely extracted, is passed through after being mixed with helper plasmid pHelper1.0, pHelper2.0
Liposome transfection 293T cells, collect the cell supernatant of culture 48h, and through centrifugation, slow virus carrier is obtained after supernatant liquid filtering
LV-IFNAR2-RNAi；
(3) by above-mentioned slow virus carrier, IFNAR2 gene siRNAs are imported into DF-1 cell lines, the table of silence IFNAR2 genes
Reach, improve viral titer of the H5N2 types avian influenza virus in DF-1 cell lines.
2. the method for IFNAR2 genes in a kind of silence DF-1 cell lines as claimed in claim 1, it is characterized in that, the lipid
Body is Lipofectamine2000.
3. the method for IFNAR2 genes in a kind of silence DF-1 cell lines as claimed in claim 1, it is characterized in that, the step
(3) following steps are specifically included：
1) by DF-1 cell inoculations into Tissue Culture Dish, when density to be grown is up to 70%, it is inoculated with slow virus LV-IFNAR2-
RNAi；
2) with containing the 10%FBS DMEM culture mediums of 10 μ g/mL polybrenes dilution LV-IFNAR2-RNAi to final concentration of 5 ×
106PFU/mL, and then by 10 times of doubling dilutions, obtain the different virus titer of at least three, be seeded to DF-1 cells respectively
In；Concurrently set positive-virus control；
3) 5%CO under the conditions of the DF-1 cells for being inoculated with LV-IFNAR2-RNAi being put 37 DEG C2Culture 4h is maintained, is changed to containing 5%
FBS DMEM culture mediums, continue culture to 48h, replace the 10%FBS DMEM culture mediums containing 4 μ g/mL puromycins, filter out
Positive cell clone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510143519.XA CN104762325B (en) | 2015-03-30 | 2015-03-30 | A kind of method of IFNAR2 genes in 1 cell lines of silence DF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510143519.XA CN104762325B (en) | 2015-03-30 | 2015-03-30 | A kind of method of IFNAR2 genes in 1 cell lines of silence DF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104762325A CN104762325A (en) | 2015-07-08 |
| CN104762325B true CN104762325B (en) | 2018-04-17 |
Family
ID=53644416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510143519.XA Expired - Fee Related CN104762325B (en) | 2015-03-30 | 2015-03-30 | A kind of method of IFNAR2 genes in 1 cell lines of silence DF |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104762325B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109295063B (en) * | 2018-10-25 | 2022-05-03 | 贵阳市妇幼保健院 | Interference sequence of IL-17 gene closely related to podocyte injury of primary nephrotic syndrome |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1622957A (en) * | 2001-12-31 | 2005-06-01 | 耶达研究发展有限公司 | IFNAR2 mutants, their production and use |
| WO2011005765A1 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Bioprocessing |
| CN103952413A (en) * | 2014-05-14 | 2014-07-30 | 广东省农业科学院动物卫生研究所 | Construction and application of IFNAR2 gene-targeting RNA interference expression vector |
-
2015
- 2015-03-30 CN CN201510143519.XA patent/CN104762325B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1622957A (en) * | 2001-12-31 | 2005-06-01 | 耶达研究发展有限公司 | IFNAR2 mutants, their production and use |
| WO2011005765A1 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Bioprocessing |
| CN103952413A (en) * | 2014-05-14 | 2014-07-30 | 广东省农业科学院动物卫生研究所 | Construction and application of IFNAR2 gene-targeting RNA interference expression vector |
Non-Patent Citations (2)
| Title |
|---|
| "Comparative analysis of selected innate immune-related genes following infection of immortal DF-1 cells with highly pathogenic（H5N1） and low pathogenic（H9N2） avian influenza viruses";Ai-ling Liu et al.;《Virus Genes》;20150104;第50卷(第2期);第189-199页 * |
| "鸡ＩＢＤＶ在微载体微型反应器ＤＦ－１细胞系上繁殖特性研究";杨霞等;《中国兽医学报》;20131031;第33卷(第10期);第1519-1526页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104762325A (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104694576B (en) | A kind of method of IFNAR1 genes in 1 cell lines of silence DF | |
| CN108315330A (en) | The sgRNA and knockout technique of CRISPR-Cas9 systemic characteristics targeting people's RSPO2 genes and application | |
| CN101805750B (en) | Construction and application of farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector | |
| CN109837306A (en) | Contain the excretion body and its preparation method and application of miRNA-204-5p | |
| CN108251384A (en) | One plant of kinds of fish Rhabdovirus attenuated vaccine strain | |
| CN104195116B (en) | A kind of recombinant Newcastle disease virus and its construction method for expressing goose parvovirus VP3 genes | |
| CN104531700B (en) | Suppress shRNA sequences and its application of mouse MACF1 gene expressions | |
| JP2016528878A (en) | Avian cells for improved virus production | |
| CN103849601A (en) | Method for inducing transdifferentiation of fibroblasts into neuronal cells and application thereof | |
| CN102206645B (en) | Mediating method of RNAi (ribonucleic acid interference) utilizing lentiviral vector | |
| CN105121634B (en) | The cell line and its production method of virus production ability with raising | |
| CN104762325B (en) | A kind of method of IFNAR2 genes in 1 cell lines of silence DF | |
| CN105039268A (en) | Recombinant duck plague virus of expressing duck tembusu virus E protein as well as construction method and application of recombinant duck plague virus | |
| CN116926022B (en) | PiNew castle disease virus mGZ of pigeon origin gene VI, application, preparation method, culture method and vaccine | |
| CN105039342A (en) | siRNA capable of inhibiting MAT2A genetic expression and application of siRNA | |
| CN103740722A (en) | shRNA (short hairpin ribonucleic acid) inhibiting retinal pigment epithelium apoptosis and application thereof | |
| CN105624162B (en) | For the siRNA of mammal R-Spondin2 gene targets, ShorthairpinRNA and carrier and application | |
| CN104745635B (en) | A kind of method of OASL genes in silence DF-1 cell lines | |
| CN102061310A (en) | Construction and application of human FHL1C eukaryotic expression vector | |
| CN103215267B (en) | Suppress siRNA and its application of influenza virus related gene | |
| CN102220377B (en) | Novel interference vector for increasing animal lean meat percentage and application thereof | |
| CN102266569A (en) | Application of miR-199a and inhibitor thereof | |
| CN104651322A (en) | Construction and culture methods of recombinant rabies virus | |
| CN110042084A (en) | A kind of production method and preparation of live virus influenza vaccines | |
| CN105368865A (en) | Controllable genome-modified plasmodium, recombinant expression vector and construction method and application of controllable genome-modified plasmodium and recombinant expression vector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230118 Address after: 250000 Room 302, No. 8, plot 4, Yinfeng international biological city, No. 1177, Chunlan Road, high tech Zone, Jinan, Shandong Province Patentee after: Shandong Yingke Weixin Bioengineering Co.,Ltd. Address before: 250023 No. 1 Jiao Tong Road, Tianqiao District, Shandong, Ji'nan Patentee before: INSTITUTE OF POULTRY SCIENCE, SHANDONG ACADEMY OF AGRICULTURAL SCIENCE |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180417 |